Category Archives: Regenerative Medicine

Dr. Ordon believes he had a bad reaction to fluoroquinolones and explains says he developed Achilles tendinitis due to cipro toxicity, which was very sore and lasted a few months. After he got an MRI, a tear in his Achilles tendon was found, and he attributes these health issues to the fluoroquinolones. To help him heal, he visited internal medicine specialist Dr. Mark Ghalili to get a customized Nad IV therapy protocol that actually helps rebuild the mitochondria within the tendon. Dr. Ghalili says the IV Therapy Dr. Ordon received helped to increase collagen production, reduce pain and increase stamina. Like Dr. Ordon, Dr. Ghalili also had a negative reaction to this type of antibiotic and says he had brain fog, could not walk or care for himself and was confined to a wheelchair for 5 months. He tells us he has treated hundreds of patients for issues related to the use of fluoroquinolones. Dr. Ordon says after enduring this health scare, he will no longer take or prescribe fluoroquinolones. He urges everyone to ask questions about the antibiotics your doctor is prescribing, like if you really need it, what are alternative options?

Read more:
Regenerative Medicine LA | Natural Medicine | Alternative ...

Discover the future of medicine

The Master of Science degree program invites you to chart the course for the medicine of the futureregenerative medicine. This is one of the first masters programs in stem cell biology and regenerative medicine in the United States.

Our one-year program offers courses in cutting-edge biomedical science, including developmental biology, human embryology, regenerative medicine, and the translational and therapeutic aspects of stem cell technology. The program also provides practical hands-on laboratory experience with the growth and differentiation of stem cells. Although not required, students are encouraged to engage in laboratory research during the year, with one of the 80+ lab groups that constitute USC Stem Cell. At the completion of the first year, students may informally continue to conduct research in their labs after receiving the MS diploma, or can petition to continue research with a guided and structured second research year culminating in a capstone thesis project.

After completing this program, you will be poised to apply to medical or PhD programs, enter the growing stem cell pharmaceutical domain, or engage in other academic, clinical or business efforts. You will possess a unique understanding of how the bodys own developmental and repair mechanisms can restore damaged cells, tissues and organsproviding new opportunities to treat conditions ranging from blindness to cancer, from organ failure to HIV/AIDS.

To apply, visit gradadm.usc.edu.

Please note that the application portal for Fall 2022 will open October 15th, 2021. The deadline to apply will be April 1st, 2022.

For questions, e-mail us at scrm@usc.edu or call (323) 865 1266.

Originally posted here:
MS in Stem Cell Biology and Regenerative Medicine

In Aragonese society, integrative and regenerative medicine has its own name: the clinic Biosalud in Zaragoza, one of the leading centers in this type of medical specialty with more than 30 years of experience behind it. In most medical conferences and symposia, it is inevitable to mention the excellent therapeutic results of this clinic.

The same can be said if we pay attention to Views of Biosalud Zaragoza To publish their patients on the Internet and on social networks, and one of their common characteristics is evaluation, which is usually on the border of excellence.

One of the things that attracts the most attention is his specialization in diagnosing Lyme disease, which is any GPs nightmare.

Lyme disease is a chameleon disorder and its symptoms can be confused with many conditions. In fact, it is one of the most difficult diseases to diagnose and a large percentage of patients are treated for years, without success, for health disorders they do not really have. Likewise, its treatment is not usually simple in all cases and it can last for several months.

Therefore, it is a bacterial infection whose source is usually the bite of a tick carrying the disease.

Contrary to popular belief, it is not a rare disease and its prevalence is increasing in developed societies.

Habits such as hunting, fishing in river areas, going out into the mountains or keeping pets, especially dogs or livestock, increase the likelihood of contracting the disease.

To detect it, it is necessary to use the most advanced diagnostic tools.

in this meaning, Biosalud Day Hospital He has his own test called Lyme CHECK which allows to start a personalized treatment protocol for each patient.

In the medical sector, it is very common to find published opinions that are not satisfied with the care provided. News of medical practice cases that may be categorized as questionable or inappropriate is also very common.

This is not the case with Biosalud Day HospitalIts clinics are rated as excellent by those who have undergone or are still undergoing treatment there.

Take a simple look at the criticisms expressed by patients Biosalud Zaragoza, we can see that positive opinions are clearly the dominant observation. The same thing happens if we take another look at the comments of the Madrid patients.

The common observation is that most of them are people who say that they have, in the past, done multiple medical reviews without finding a satisfactory solution to their health problems.

If you are looking for a second medical opinion or a treatment that truly meets your expectations, in Zaragoza and Madrid you can access the most advanced integrative and regenerative medicine benefits.

With more than 35 years of experience in both fields, in Biosalud Day Hospital They are pioneers in the application of innovative diagnostic systems and integrative therapy for all types of diseases. And not only that, but they also specialize in innovative biological therapies and in detecting overlapping or hidden conditions, such as Lyme disease.

Our advice is to never throw in the towel, assuming you cannot improve your ailments, and you are invited to seek an initial consultation at this centre. If you do, it may not be long before you join the patients publicly expressing their appreciation for medical professionals in clinics. Biosalud.

Visit link:
Integrative and Regenerative Medicine in its Own Name: Biosalud Clinic in ... - Sunday Vision

Covington, Kentucky--(Newsfile Corp. - October 13, 2021) - CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announced plans today to offer contract development and manufacturing services. CTI will launch the new initiative, focusing on offerings that will enhance cell and gene therapy capabilities.

The announcement was made during a special company presentation at the Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa.

CTI has been on the forefront of life-changing medicine for more than 20 years, working on breakthroughs from some of the earliest developments in immunosuppression to recent discoveries in regenerative medicine. As advancements in medicine trend towards personalized medicine and targeted regenerative therapies, demand for manufacturing capacity has increased, creating a manufacturing shortage.

The facility is estimated to be approximately 40,000 square feet and will initially focus on viral vector manufacturing, ideally to support emerging companies who face challenges in manufacturing priority.

"The decision to build out contract development and manufacturing capabilities was two-fold. First, we are always looking to better serve our biotechnology and biopharmaceutical sponsors and help facilitate the most seamless, efficient clinical trial process possible. Providing manufacturing services will help us better meet the needs of our clients working in the cell and gene therapy space," explains Tim Schroeder, CEO and Chairman of CTI. "Second, and arguably more importantly, we see major challenges that could delay medical advancements and ultimately impact patient lives. If capacity maintains at current levels, manufacturing shortages have the potential to significantly delay future developments in personalized medicine and treatments and cures for disease. Our expertise and resources create a unique position for CTI to make a difference, so we're moving forward to begin to address the challenge."

Story continues

The decision to enter into the manufacturing arena follows the company's announcements about expanding laboratory services to support rare disease and cell & gene therapy research across all regions of the world, with a flagship lab set to open in Cincinnati, OH (covering the Americas), and with the acquisition of Dynakin Labs, we will have laboratory services to support Europe and the MEA region. Offering manufacturing, regulatory development and strategy, clinical operations, research site, laboratory, and real-world evidence services, CTI is the only global research service provider with a history of success in regenerative medicine spanning decades and the ability to support cell and gene therapy programs throughout the entire clinical development lifecycle. The company's regenerative medicine experience includes work with more than 1,000 sites, and its current operations can support cell and gene therapy programs in any location across the globe.

"We believe cures for debilitating diseases and prevention of catastrophic illnesses are possible with advances in fields such as regenerative medicine and personalized curative therapies," adds Lynn Fallon, President and Vice-Chair of CTI. "We are privileged to be in a leadership role for these exciting and life-changing projects, and we're looking forward to seeing how our team's and our partners' work will change the medical landscape."

CTI, now in its third decade, is one of the 20 largest CROs in the world with associates in more than 60 countries across six continents. The company was recently named the #1 CRO in the world for operational excellence at the 2021 CRO Leadership Awards, outperforming dozens of other recognized CROs from around the world. More information about CTI's work in COVID-19 and other complex disease areas can be found at http://www.ctifacts.com.

About CTI

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI's focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI is currently part of more than 30 active COVID-19 projects for treatment and prevention. CTI also offers a fully integrated multi-specialty clinical research site, as well as complete global laboratory services. Now in its third decade, it is one of the 20 largest CROs in the world with associates in more than 60 countries across six continents. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, MEA and Asia-Pacific. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations and for moving medicine forward. For more information visit http://www.ctifacts.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99565

Read the original:
CTI Announces Contract Development and Manufacturing Initiative During Alliance for Regenerative Medicine Meeting on the Mesa - Yahoo Finance

DUESSELDORF, Germany--(BUSINESS WIRE)--The kick-off for the first SmartMed network meeting (digital) took place on Thursday, October 14th. Almost all network partners were able to attend the 2.5-hour event and exchanged ideas on current and potential projects. The focus here was on getting to know each other as well as targeted networking. With the help of a modern network platform, the participants were encouraged to exchange ideas in virtual chat rooms about the topics of digitization and artificial intelligence, new materials for restoring or healing tissue and organs and new approaches to stem cell therapy.

The next network meeting is planned for the beginning of December 2021. The network partners largely determine the focus of the next meeting themselves; Depending on requirements, either a cross-network workshop or a lecture on a specific topic from the field of regenerative medicine is prepared.

About SmartMed:The international ZIM cooperation network "Regenerative Solutions for Tomorrow's Therapy" is funded by the Federal Ministry for Economic Affairs and Energy as part of the ZIM program (Central Innovation Program for SMEs). The network management of Silversky LifeSciences GmbH launched the association with technological competencies from blockchain to the regulation of medical devices at the beginning of July 2021. Networking is coordinated by Silversky LifeSciences with its business start-up experts with a technology focus in LifeSciences and with extensive experience in the financing, operation, and development of innovative small and medium-sized companies in this sector. "Each partner brings a certain specialist knowledge and thus a unique contribution to the value chain into the network", describes Dr. Mirko Stange, founder, and CEO of Silversky LifeSciences, the win-win situation for everyone involved.

The international focus is on UK, which also offers German network partners a good opportunity to react to the new framework conditions, especially after Brexit and the associated reorganization of international cooperation. The project is supported by the international network management team Maria Fenner, Lena Ehrenpreis and Jessica Stolzenberg. "The aim of the network is to network companies with R&D institutions in order to initiate a lively innovation policy, to promote startups and to promote the exchange and cooperation of regenerative medicine with related industries", says Jessica Stolzenberg. We want to give all SMEs and startups in the industry the opportunity to expand their network and find new cooperation partners. If there is still funding for my own research activities, I don't know who would turn it down, says Lena Ehrenpreis. Maria Fenner adds: Our focus is on the entire field of regenerative medicine and the development of innovative, regenerative therapies, which are based on the latest scientific findings and use the most modern technologies. The focus is on restoring the healthy and functional original state of the affected tissue / organ by linking modern therapeutic approaches, new and functional materials, as well as the use of digital and intelligent systems in the form of algorithms, deep learning and AI. "

The support provided by the network includes advice and practical help with the market launch, applying for grants, close collaboration between experts in order to research or optimize new therapy methods and to bring products to market maturity. All interested parties are cordially invited to contact the network managers to join the discussion, make contacts and start exciting projects.

Read more from the original source:
International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire

Question: You are known for your expertise in hormone replacement therapy. What otherareas of medicine do you specialize in?

Answer: I am board certified in primary care, metabolic cardiology, and chiropractic medicine.I am also board certified in physician weightmanagement, anti-aging medicine, aesthetic medicine and physiotherapy. I specialize in anti-aging and regenerative medicine, and I also treat patients who are in need of hormone replacement, cardiac management, mens and womens sexual health, and primary andurgent care. I offer my clients a holistic and personalized approach to healthcare.

Question: People assume that because you dont participate with insurance, yourservices are expensive. Is this true?

Answer: No. Its a misconception as far as pricing. We are able to utilize an individualsinsurance for diagnostic testing and certain medications. The patient pays us directlyfor our services, therefore our time is notlimited with each patient. This allows us to create a dialog and grow a relationship.My goal is to provide health care to everyone regardless of insurance, and our pricesare affordable for everyone.

851 Dunlawton Ave.

STE 104

Port Orange, FL 32127

http://www.anti-agingdocs.com

(386) 366-7418

Continue reading here:
Anti-Aging & Regenerative Associates | In The Know | hometownnewsvolusia.com - Hometown News

Orthocells CelGro platform forms the basis of a specialised collagen rope that could help reconstruct the anterior cruciate ligament, a strong band of tissue linking the thigh and shin bones that can rupture during athletic activity.

() is ready to make waves in the regenerative medicine space with a well-diversified portfolio of drugs at its disposal, according to Pitt Street Researchs Stocks Down Under newsletter.

The companys portfolio includes CelGro for soft tissue repair and dental bone regeneration, Ortho-ATI for tendon regeneration and Ortho-ACI for cartilage regeneration.

Pitt Street believes that as Orthocell continues to further research and trial its therapies, it will be able to address a much larger portion of the market.

The following is an extract from the Stocks Down Under newsletter:

Orthocell listed on the ASX in 2014 and initially had two main products: Ortho-ATI and Ortho-CTI. OrthoATI was the companys lead product for tendon regeneration, with Ortho-CTI being developed for cartilage regeneration. Lastly, the company was in late-stage development for its tissue regeneration technology, called CelGro, with initial human trials underway.

Cartilage tissue is the main connective tissue in the human body and is widely found in joints and bones. Ortho-CTI uses healthy cartilage cells (by extracting healthy articular cartilage from the patient through surgery) and uses it to grow healthy tissue over five weeks. These cells are then deployed into the joint through surgery, where they begin to generate new cartilage, hopefully resulting in complete recovery of the joints over 6-9 months.

Ortho-ATI, on the other hand, is used to treat damaged tendons. It makes use of healthy tendons (using a sample extracted through a biopsy) to cultivate tendon cells in a lab. These cells are then injected into the affected tendon around 4-5 weeks after the biopsy using ultrasound guidance. By late 2015, Ortho-ATI was being used commercially and had already been used to treat over 300 patients.

Ortho-CTI also saw sporadic use in Australia and Southeast Asia. The company was granted patents in numerous jurisdictions, including the US, Australia and Hong Kong, for its various products during this time and continued to expand its clinical presence across Asia. In November 2015, Ortho-CTI was used for the first time on a patient in Singapore.

Despite having access to early commercial opportunities, Orthocell continued to commission clinical trials for Ortho-ATI, mainly to determine its effectiveness against alternatives, such as surgery. One such trial began in July 2016, with results showing that Ortho-ATI was less invasive than traditional treatments (e.g., cortisol injections and physiotherapy) and showed significantly better results.

By the end of 2016, CelGro had also performed extremely well in early-stage clinical trials. It had shown safety and tolerability for being used as a barrier membrane to allow bone growth in dental applications and to treat full-thickness tendon tears.

November 2017 was a pivotal month for the company. Not only did Orthocell treat its 1,000th patient, but it also received CE Mark for CelGro. CE Mark is regulatory approval that allows the specified drug to be sold and marketed in the European Union. CelGro was used for the first time within the EU in May 2018.

Prior to that, in October 2016, the company received approval for a human nerve regeneration study using CelGro. The first results were published in May 2019, showing an 83% improvement in muscle power, which indicated that CelGro could be used to support nerve regeneration.

CelGro further showed an 89% success rate in tendon regeneration and a 96% success rate in nerve repairs in quadriplegic patients in later studies. All these successful studies and the various use-cases for CelGro implied a potential addressable market of over US$2bn, which leads us to believe that Orthocell is not going to find it difficult to grow its business worldwide once approvals are in place.

In December 2020, Orthocell received market approval for CelGro in Australia for dental bone and tissue regeneration. Shortly after, the company received FDA 510(k) clearance, allowing Orthocell to market and supply CelGro in the US.

As of now, CelGro has only obtained approval for a small percentage of its total use cases. We believe that as Orthocell continues to further research and trial its therapies, it will be able to address a much larger portion of the market.

The company is currently busy securing patents for CelGro in multiple jurisdictions. On top of that, Ortho-ATI and CTI continue to show extremely positive results when compared to traditional regenerative treatments.

We believe that Orthocell will continue to go from strength to strength as it further expands its operations and offers its treatments to more patients. This is evident in the companys financial performance as revenue increased 21% in 1HY21 ($446,201) over the corresponding period and other revenues increased by 500% ($228,664). With over $17m in cash at the end of 1HY21, the company has financial runway for the two to three years. By that time, we believe Orthocell should be able to become profitable.

Keeping all these factors in mind, we think Orthocell is a four-star opportunity. While already having numerous products out in the market, we believe the company can leverage its current technology to address many other unmet needs in the regenerative medicine space. We expect Orthocell to continue to seek approval for other use-cases, such as nerve regeneration, vastly expanding its addressable market in the years to come.

Original post:
Orthocell is ready to make waves in the regenerative medicine space: Pitt Street Research - Proactive Investors Australia

Amniotic Products Market: Overview

The amniotic products market is estimated to observe considerable growth during the forecast period of 2021-2031. The growing incidence of burn injuries among a considerable chunk of the global populace coupled with an increase in the awareness programs will assure steady growth for the amniotic products market.

The growing number of traumatic wounds and the rise in ophthalmology, orthopedic, and cosmetic surgeries will have a profound impact on the growth of the amniotic products market. Amniotic-derived products are a subtype of orthobiologic, examined as a latent treatment option through amplification of joint inflammation and healing. The heightening use of these products in several healing applications will present a plethora of growth opportunities for the global market.

Read Report Overview - https://www.transparencymarketresearch.com/amniotic-products-market.html

The use of amniotic products has evolved considerably over the years. The growing use of amniotic membranes for a plethora of conditions related to ophthalmology such as retinal detachments, corneal surface lesions, and limbal stem cell generation will invite exponential growth for the amniotic products market. Furthermore, the research into amniotic products has increased extensively over the years, especially across orthopedics. Hence, these factors will have a profound impact on the growth of the amniotic products market.

Transparency Market Research (TMR) has obtained considerable information on the overall growth trajectory of the amniotic products market. The upcoming report on the amniotic products market gives a detailed insight about diverse growth aspects. Furthermore, the COVID-19 impact is also included in the report.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_83262

TMR W.I.N Approach

TheW.I.N(Wholesome Competitive Insights.Important Trends.Noteworthy Regions.) Approach makes TMR one of the best research companies in the industry. This approach assures on-point information to the stakeholders and the CXOs.

Amniotic Products Market: Wholesome Competitive Insights

The amniotic products market has numerous players. The players formulate numerous strategies and methods to increase their consumer base. Research and development activities are one of them. The players invest in these activities for accelerating developments and finding insights. All these activities eventually add value to the growth trajectory of the amniotic products market.

Strategic collaborations are of immense importance for the amniotic products market. Mergers, acquisitions, joint ventures, and partnerships help in strengthening the influence of the players in the amniotic products market. All these aspects ultimately contribute to the growth of the amniotic products market.

Some well-established players in the amniotic products market are Integra LifeSciences, Lucina Biosciences, LifeCell International Pvt. Ltd., Orthoflix Medical Inc., and MTF Biologics.

Request for Analysis of COVID-19 Impact on Amniotic Products Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_83262

Amniotic Products Market: Important Trends

Growing Incidences of Burn Injuries to Invite Considerable Growth for Amniotic Products Market

Cases related to burn wounds and injuries have increased extensively over the years. The World Health Organization (WHO) states that nearly 180000 deaths are caused due to burns every year. The statistics by the WHO further highlight that more than 1000000 people are moderately or severely burnt every year. These statistics shed light on the need for treatment to decrease the effect of the wounds. As amniotic products are used for healing such wounds, the demand is expected to increase.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_83262

Implementation of Acts and Numerous Government Initiatives to Accelerate Regenerative Medicine Research brings Considerable Growth Opportunities

Many countries are focusing on boosting research in regenerative medicine. This aspect may have a great impact on the growth of the amniotic products market. Fast-track approvals for novel regenerative medicine products and other factors are also looked upon by introducing various acts and initiatives. Therefore, these factors will bring good growth prospects.

Pre Book Amniotic Products Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_83262&ltype=S

Amniotic Products Market: Noteworthy Regions

The amniotic products market in North America is estimated to observe a dominant stance during the forecast period. The introduction of laws like the 21stCentury Cures Act by the U.S. assures promising growth. Asia Pacific is expected to observe moderate growth during the forecast period.

More Trending Reports by Transparency Market Research:

Interventional Radiology Market According to Transparency Market Researchs latest report on the global Interventional Radiology market for the historical period20172018and forecast period20192027,high incidence of cancer, awareness programs by governments and NGOs, increase in maternal age and late pregnancies are projected to drive the global Interventional Radiology market during the forecast period

Inhalation and Nasal Spray Generic Drugs Market According to the report, the global inhalation and nasal spray generic drugs market was valued atUS$ 27.5 Bnin2018and is anticipated to expand at a CAGR of4.80%from2019to2027

Life Sciences BPO Market Gene therapies, intelligent drug discovery, telemedicine, and the likes are bringing about a change in the life sciences BPO market. Companies in the market for life sciences BPO are innovating through AI and machine learning (ML) for drug discovery.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Go here to see the original:
Amniotic Products Market: Growing incidence of burn injuries to drive the market - BioSpace

- Collaboration to Leverage Omega Epigenomic Controllers, a New Class of mRNA Therapeutics as Programmable Epigenetic Medicines, for Ocular Diseases by Targeting and Controlling Specific Ocular Disease Genes

Published: Oct. 14, 2021 at 6:00 AM CDT

CAMBRIDGE, Mass., Oct. 14, 2021 /PRNewswire/ --Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammation or regeneration of ocular tissues.

Under the terms of the collaboration, Omega and members of the Ophthalmology Department of Stanford University School of Medicine will use the OMEGA Epigenomic Programming platform to discover and research novel ocular targets for potential futureOEC development candidates. Albert Wu, M.D., Ph.D., FACS, Associate Professor of Ophthalmology, will serve as principal investigator. Other contributors will include Jeffrey Goldberg, M.D., Ph.D., Professor and Chair of Ophthalmology, and Michael Kapiloff, M.D., Ph.D., Associate Professor (Research) of Ophthalmology.

"Through this research collaboration, we aim to expand the reach of our OMEGA platform within regenerative medicine, immunology, and inflammation with ocular disease targets," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "We will continue exploration of the broad potential of our disruptive platform and OECs, our new class of mRNA therapeutics as programmable epigenetic medicines."

Detailed financial terms of the collaboration were not disclosed.

About Omega Therapeutics

Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform. The OMEGA platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

For more information, visitomegatherapeutics.com, or follow us onTwitterandLinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations for the collaboration with Stanford and our OMEGA Epigenomic ProgramingTMplatform.These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights.These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form10-Q for the period ended June 30, 2021and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Investor contact: Kevin Murphy/Brendan BurnsArgot Partners 212.600.1902 ArgotOmega@argotpartners.com

Media contact: David Rosen Argot Partners 212.600.1902 david.rosen@argotpartners.com

View original content to download multimedia:

SOURCE Omega Therapeutics

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Continue reading here:
Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine - KALB News

Gloria Clemons gives a COVID-19 vaccine to Navy veteran Perry Johnson at the Edward Hines, Jr. VA Hospital in Hines, Ill., in September. Scott Olson/Getty Images hide caption

Gloria Clemons gives a COVID-19 vaccine to Navy veteran Perry Johnson at the Edward Hines, Jr. VA Hospital in Hines, Ill., in September.

Conventional wisdom says that if you're vaccinated and you get a breakthrough infection with the coronavirus, you can transmit that infection to someone else and make that person sick.

But new evidence suggests that even though that may happen on occasion, breakthrough infections might not represent the threat to others that scientists originally thought.

Ross Kedl, an immunologist at the University of Colorado School of Medicine, will point out to anyone who cares to listen that basic immunology suggests the virus of a vaccinated person who gets infected will be different from the virus of an infected unvaccinated person.

That's because vaccinated people have already made antibodies to the coronavirus. Even if those antibodies don't prevent infection, they still "should be coating that virus with antibody and therefore helping prevent excessive downstream transmission," Kedl says. And a virus coated with antibodies won't be as infectious as a virus not coated in antibodies.

In Provincetown, Mass., this summer, a lot of vaccinated people got infected with the coronavirus, leading many to assume that this was an example of vaccinated people with breakthrough infections giving their infection to other vaccinated people.

Kedl isn't convinced.

"In all these cases where you have these big breakthrough infections, there's always unvaccinated people in the room," he says.

In a recent study from Israel of breakthrough infections among health care workers, the researchers report that in "all 37 case patients for whom data were available regarding the source of infection, the suspected source was an unvaccinated person."

It's hard to prove that an infected vaccinated person actually was responsible for transmitting their infection to someone else.

"I have seen no one report actually trying to trace whether or not the people who were vaccinated who got infected are downstream and certainly only could be downstream of another vaccinated person," Kedl says.

There's new laboratory evidence supporting Kedl's supposition. Initially, most vaccine experts predicted that mRNA vaccines like the ones made by Pfizer and Moderna that are injected into someone's arm muscle would generate only the kinds of antibodies that circulate throughout the body.

But that might not be the whole story.

"I think what was the big surprise here is that the mRNA vaccines are going beyond that," says Michal Caspi Tal, until recently an instructor at Stanford University's Institute for Stem Cell Biology and Regenerative Medicine and now a visiting scientist at the Massachusetts Institute of Technology.

What Tal has found is that in addition to the circulating antibodies, there was a surprisingly large amount of antibodies in mucosal membranes in the nose and mouth, two of the primary entry points for the coronavirus.

Immunologist Jennifer Gommerman of the University of Toronto found this as well.

"This is the first example where we can show that a local mucosal immune response is made, even though the person got the vaccine in an intramuscular delivery," Gommerman says.

If there are antibodies in the mucosal membranes, they would likely be coating any virus that got into the nose or throat. So any virus that was exhaled by a sneeze or a cough would likely be less infectious.

Gommerman says that until now, it seemed likely that a vaccine that was delivered directly to the mucosal tissue was the only way to generate antibodies in the nose or throat.

"Obviously a mucosal vaccination would be great too. But at least we're not sitting ducks," Gommerman says. "Otherwise everyone would be getting breakthrough infection."

Now, these studies by Gommerman and Tal have yet to undergo peer review, and some have already suggested that the antibodies they have described may not confer true mucosal immunity.

But there's other evidence that a vaccinated person's breakthrough infection may not transmit efficiently to others.

Marion Pepper, an immunologist at the University of Washington, says a recent study from the Netherlands looked at how well virus from vaccinated people could infect cells in the lab.

Pepper says the answer was not well.

"If you actually isolate virus from people who are getting a secondary infection after being vaccinated, that virus is less good at infecting cells," Pepper says. "It's not known why. Is it covered with an antibody? Maybe. Has it been hit by some other kind of immune mediators, cytokines, things like that? Maybe. Nobody really knows. But the virus does seem to be less viable coming from a vaccinated person."

More studies are emerging that suggest there's something different about the virus coming from a vaccinated person, something that may help prevent transmission.

Whatever it is, the University of Colorado's Kedl says it's one more reason that getting vaccinated is a good idea.

"Because you're going to be even more protected yourself. And you're going to be better off protecting other people."

Kedl says that's what you call a win-win situation.

See the rest here:
What the latest COVID research says about breakthrough cases and transmission : Shots - Health News - NPR